Otsuka America Pharmaceutical's kidney drug Samsca, or tolvaptan, may cause irreversible and potentially deadly liver injury, and providers should promptly conduct liver tests on patients reporting symptoms, according to the FDA. Otsuka informed the FDA that three trial participants who took tolvaptan developed liver problems, and their conditions improved after they stopped taking the drug.
FDA warns of liver injury risk from tolvaptan
SmartBrief Job Listings for Health Care
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
|Assistant Vice President - Dental Director||